ArticleCell communication and signaling : CCS2026
Secreted RCN3 acts as an early epithelial-fibroblast mediator via TGFβR1-Smad signaling in post-ALI pulmonary fibrosis.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pulmonary fibrosis (PF), driven by dysregulated epithelial-fibroblast interactions, contributes to poor outcomes after acute pneumonia. However, early profibrotic paracrine mediators released by injured epithelium remain incompletely defined. Using secretomics of LPS-treated pulmonary epithelial cells, we identified Reticulocalbin 3 (RCN3) as an epithelial paracrine mediator. In clinical bronchoalveolar lavage fluid (BALF) samples, RCN3 was significantly higher in organizing pneumonia patients undergoing active fibrotic organization than in idiopathic PF patients in a stable fibrotic state. In LPS-induced acute lung injury (ALI) mice, BALF RCN3 peaked earlier than TGFβ1/FGF2/CTGF, indicating an early role in PF. Mechanistically, epithelial RCN3 is secreted via an N140-glycosylation–dependent ER-Golgi pathway and engages TGFβR1, activating canonical Smad2/3 signaling in fibroblasts; RCN3 also upregulates TGFβ1 and TGFβR1/2 in a Smad3-dependent manner. In vivo, intratracheal exogenous RCN3 administration, in the absence of LPS, was sufficient to trigger fibrosis, whereas early-phase neutralization of RCN3 after LPS-ALI attenuated fibrotic remodeling. Collectively, these findings identify secreted, stress-responsive RCN3 as an early epithelial paracrine mediator engaging TGFβR1-Smad2/3 signaling and nominate it as a potential early-window therapeutic target for post-ALI pulmonary fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.